Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits - WSJ

Published 30/09/2019, 22:58
Updated 30/09/2019, 23:00
Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits - WSJ

Drugmakers look to use Purdue Pharma's bankruptcy to settle opioid suits - WSJ

(Reuters) - Endo International Plc (O:ENDP), Johnson & Johnson (N:JNJ) and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person familiar with the matter.

Five drugmakers battling the cases - Endo, J&J, Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA) , Allergan Plc (N:AGN) and Mallinckrodt Plc (N:MNK) - are looking to enact a global settlement of the litigation that would be implemented through Purdue's Chapter 11 case, the WSJ reported citing a person familiar with the matter.

The mechanism, if successful, would allow the companies to contribute money into a trust set up through the bankruptcy in exchange for a complete release from liability, according to the report. (https://on.wsj.com/2nVksYH)

OxyContin maker Purdue filed for bankruptcy protection in September, succumbing to pressure from more than 2,600 lawsuits alleging the company helped fuel the deadly U.S. opioid epidemic.

Purdue, Mallinckrodt, Endo, J&J, Teva and Allergan were not immediately available to Reuters' requests for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.